Drafted
claude-sonnet-5 · 2026-09-21
Independent verification — revise
claude-opus-5 · 2026-09-21
Reviewer's reasons
- Quote is verbatim operative regulatory text at 21 CFR 202.1(e)(3)(i) ('Scope of information to be included; applicability to the entire advertisement'), not an example, definition, or preamble gloss. It is a mandatory 'shall', so the obligation framing is faithful.
- The 'within that same part or theme' element of the check is reinforced by the immediately preceding sentence in the same subparagraph: 'Untrue or misleading information in any part of the advertisement will not be corrected by the inclusion in another distinct part of the advertisement of a brief statement containing true information...'. So the check follows from the source read in context.
- Determinism 'judgment' is right: whether an omission renders a part or theme misleading, and whether the supplied qualification is appropriate, turns on materiality and impression, not presence/absence of a literal string.
- Authority 'binding' is right (codified regulation), and 'blocker' severity is defensible since failure implicates the (e)(1) true-statement requirement and section 502(n).
- Atomic: the concision allowance is a conditional carve-out to the single obligation rather than a second independently checkable requirement.
- Overstated on scope: 21 CFR 202.1 governs prescription drug advertisements. The bare 'promotional' applies_when extends the rule to promotional labeling (Part 201 / 502(a)) and non-prescription materials that this section does not reach. The source's own scope limit is missing.
- The parenthetical materially loosens the source's condition. The regulation permits concision only if supplemented by a 'prominent reference on each page' to the presence and location elsewhere of a more complete discussion. The rule states only 'if referenced to a fuller discussion elsewhere', dropping both prominence and the per-page requirement, so a reviewer applying the rule could accept a single buried cross-reference the regulation would not allow.
Revised by the drafter
claude-sonnet-5 · 2026-09-21
Independent verification — revise
claude-opus-5 · 2026-09-21
Reviewer's reasons
- Supported: the quote is operative regulatory text within 21 CFR 202.1(e)(3)(i) ('shall include'), not an example, definition, or preamble. Both limbs of the rule (qualification must appear in the offending part/theme; concise qualification permitted only when supplemented by a prominent cross-reference) are stated directly in the cited sentence.
- The check's requirement that the referenced fuller discussion actually exist is a fair inference from 'a prominent reference on each page to the presence and location elsewhere in the advertisement of a more complete discussion' — a reference to a non-existent discussion cannot satisfy the proviso.
- Determinism 'judgment' is correct: 'false or misleading,' 'appropriate qualification,' 'pertinent information,' and 'prominent' all turn on impression, materiality, and adequacy rather than literal presence or absence.
- Authority 'binding' is correct: 21 CFR 202.1 is a codified FDA regulation, and (e)(3)(i) is mandatory ('shall').
- Severity 'blocker' is defensible: (e)(3)(i) sits within the true-statement requirement whose failure renders the advertisement violative of section 502(n) of the act, per (e)(5) and (e)(6) in the same source.
- Atomic: the concise-qualification proviso is the exception built into the same obligation rather than an independently checkable second requirement; separating them would produce an incomplete statement of the duty.
- Locator 21 CFR 202.1(e)(3)(i) is accurate — the quoted sentence appears verbatim in paragraph (e)(3)(i) of the source text.
- DEFECT — the rule misstates the page scope of the cross-reference. The regulation requires 'a prominent reference on each page'; the rule statement says 'that same page carries a prominent reference' and the check says 'verify that the same page contains' the reference. In a multi-page advertisement the regulation requires the reference on every page, so the rule as written would wrongly clear a piece carrying the pointer only on the page bearing the abbreviated qualification.
- SECONDARY — applies_when.product-type is ['drug'], which is broader than the source. 21 CFR 202.1(e) governs advertisements for prescription drugs; the rule statement and check carry that limit but the scoping field does not, so the rule can trigger on OTC drug material outside the cited authority.
- Not overstated: the rule does not convert guidance into obligation, does not extend beyond prescription drug advertisements in its statement, and does not harden 'may be misleading' into a flat prohibition. Its deviations from source are under-inclusive rather than over-inclusive.
Revised by the drafter
claude-sonnet-5 · 2026-09-21
Independent verification — revise
claude-opus-5 · 2026-09-21
Reviewer's reasons
- The quote is operative regulatory text ('shall include') from 21 CFR 202.1(e)(3)(i), not an example, definition, or preamble summary; the rule statement restates it without strengthening it.
- The concise-qualification allowance is correctly rendered as a conditional permission ('permitted only if supplemented by a prominent reference on each page') rather than being inverted into a freestanding obligation.
- 'judgment' is correct: whether an omission renders a part or theme misleading, and whether a cross-reference is 'prominent,' both turn on adequacy and impression, not literal presence/absence. The escalate-when clause correctly targets those two judgment points.
- 'binding' is correct — this is a codified regulation, not guidance.
- 'blocker' severity is defensible: a misleading omission in a prescription drug advertisement goes to compliance with section 502(n) and is directly enforceable.
- Locator (e)(3)(i) is exact for the quoted sentence.
- Atomic: the cross-reference requirement is a proviso conditioning the concise-qualification option, not an independently checkable second obligation.
- The check's inference that the referenced 'more complete discussion' must actually exist in the advertisement is fairly entailed by the quoted words 'the presence and location elsewhere in the advertisement of a more complete discussion.'
- Scope is overbroad: applies_when covers all prescription drug advertisements, but (e)(3) is captioned 'Scope of information to be included' as an elaboration of the (e)(1) true-statement requirement, and (e)(2) — present in the same source excerpt — exempts reminder advertisements, bulk-sale drug advertisements, and prescription-compounding drug advertisements from (e)(1). The mismatch is operationally significant because a reminder advertisement 'shall contain only' the enumerated elements, so applying this rule to one would demand content the regulation prohibits.
- Minor: 'prominent reference on each page' is a print-format concept; the check's page-by-page sweep should not be read as demanding a page inventory for broadcast-format advertisements governed by (e)(1)(i)-(ii).